Technical Analysis for EYEG - AB Corporate Bond ETF
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | N/A | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Narrow Range Bar | Range Contraction | 0.10% | |
Overbought Stochastic | Strength | 0.10% | |
Down 3 Days in a Row | Weakness | 0.10% | |
Down 4 Days in a Row | Weakness | 0.10% | |
Gapped Down | Weakness | 0.10% | |
Narrow Range Bar | Range Contraction | -0.48% | |
Overbought Stochastic | Strength | -0.48% | |
Down 3 Days in a Row | Weakness | -0.48% |
Get a Trading Assistant
AB Corporate Bond ETF Description
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Classification
Keywords: Pharmaceutical Disease Stem Cell Eye Diseases Macular Edema Diabetic Macular Edema Uveitis Allergic Conjunctivitis Dry Eye Disease Hyaluronic Acid Conjunctivitis Lineage Cell Therapeutics Viral Conjunctivitis Medical Signs Non Infectious Posterior Uveitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 35.7828 |
52 Week Low | 34.9178 |
Average Volume | 222 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 0.00 |
20-Day Moving Average | 35.28 |
10-Day Moving Average | 35.46 |
Average True Range | 0.10 |
RSI (14) | 51.46 |
ADX | 9.97 |
+DI | 49.96 |
-DI | 47.85 |
Chandelier Exit (Long, 3 ATRs) | 35.33 |
Chandelier Exit (Short, 3 ATRs) | 35.23 |
Upper Bollinger Bands | 35.71 |
Lower Bollinger Band | 34.85 |
Percent B (%b) | 0.59 |
BandWidth | 2.43 |
MACD Line | 0.03 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0246 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 35.36 | ||||
Resistance 3 (R3) | 35.36 | 35.36 | 35.36 | ||
Resistance 2 (R2) | 35.36 | 35.36 | 35.36 | 35.36 | |
Resistance 1 (R1) | 35.36 | 35.36 | 35.36 | 35.36 | 35.36 |
Pivot Point | 35.36 | 35.36 | 35.36 | 35.36 | 35.36 |
Support 1 (S1) | 35.36 | 35.36 | 35.36 | 35.36 | 35.36 |
Support 2 (S2) | 35.36 | 35.36 | 35.36 | 35.36 | |
Support 3 (S3) | 35.36 | 35.36 | 35.36 | ||
Support 4 (S4) | 35.36 |